Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provided informed consent~* Adult men or women \>= 18 years~* Chronic plaque psoriasis for at least 6 months~* Baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and Physician's Global Assessments score \>= 3~* Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy~* Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Erythrodermic, guttate, generalized pustular form of psoriasis~* History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol~* Congestive heart failure~* History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease~* Concurrent malignancy or a history of malignancy as described in the protocol~* History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)~* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug in the UK, Czech Republic, Germany, and France, and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 5 months following the last dose in France and within 10 weeks in all other countries~* Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CZP 200 mg (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.
- CZP 400 mg (Type: EXPERIMENTAL): Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.
- Etanercept (Type: ACTIVE_COMPARATOR): Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~* Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~* Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).